Insomnia is a clinically significant condition characterized by difficulty initiating sleep, maintaining sleep, and/or early-morning awakening, with resultant daytime impairment. It is not simply a subjective complaint; modern sleep medicine defines insomnia as a disorder of sleep-wake regulation involving hyperarousal, dysregulated homeostatic and circadian processes, and altered sleep architecture. When a person reports that “sleep is not coming” or “sleep is broken,” the underlying issue may involve increased cognitive and physiological arousal, misalignment of circadian timing, insufficient sleep opportunity, or maladaptive behaviors that perpetuate sleep loss.
Core mechanisms of insomnia center on a state of persistent hyperarousal. Hyperarousal involves heightened activity of stress-related systems such as the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system. This heightened arousal is measurable through increased electroencephalographic (EEG) activation, higher heart rate variability stress signatures, and elevated nocturnal cortisol in some phenotypes. Hyperarousal also includes cognitive mechanisms: worry about sleep, attentional monitoring for sleep onset, and catastrophic interpretations of normal night awakenings. Together, these processes amplify arousal signals and undermine the normal transition into sleep.
Insomnia also reflects disruption of sleep architecture. Normal sleep cycles involve non-rapid eye movement (NREM) stages progressing from N1 to N2 and then N3 (slow-wave sleep), followed by rapid eye movement (REM) sleep. Insomnia can lead to reduced total sleep time, prolonged sleep latency, increased wake after sleep onset (WASO), and fragmented transitions between stages. Some individuals exhibit diminished slow-wave sleep and altered REM density, which can contribute to non-restorative sleep and impaired emotional regulation.
Etiologically, insomnia is commonly categorized as acute, chronic, or related to comorbid conditions. Chronic insomnia disorder typically persists for at least 3 months and occurs at least 3 nights per week, with daytime symptoms such as fatigue, impaired concentration, irritability, depressed mood, and reduced quality of life. Risk factors include psychological stress, trauma exposure, depression and anxiety disorders, substance use (including caffeine, nicotine, and alcohol), shift work, chronic pain, gastroesophageal reflux, restless legs syndrome, and medications that affect arousal or circadian timing (e.g., certain antidepressants, stimulants, corticosteroids).
A key clinical concept is the interaction between homeostatic sleep drive and circadian timing. Insomnia can be driven by misalignment between the circadian “clock” and the desired sleep window, especially in delayed sleep-wake phase, advanced phase, or irregular schedules. Individuals may develop conditioned arousal: repeated pairing of the bed with wakefulness, which trains the brain to remain alert in the bedroom environment. This conditioning makes sleep onset harder and reinforces insomnia-maintaining behaviors.
Assessment emphasizes both sleep symptoms and functional impact. Clinicians collect a detailed sleep history, screen for comorbidities (mood disorders, anxiety, substance use, pain, sleep-disordered breathing), and evaluate medication effects. Sleep diaries and validated questionnaires such as the Insomnia Severity Index can quantify severity. Polysomnography is not routinely required for uncomplicated insomnia but may be indicated when obstructive sleep apnea, periodic limb movement disorder, or other sleep disorders are suspected.
Treatment is evidence-based and typically begins with cognitive behavioral therapy for insomnia (CBT-I), the first-line intervention for chronic insomnia. CBT-I includes stimulus control therapy (reassociating bed with sleep by limiting wake time in bed), sleep restriction therapy (consolidating time in bed to increase sleep efficiency), cognitive restructuring (reducing maladaptive beliefs about sleep), and relaxation or mindfulness-based techniques. These interventions target the perpetuating arousal and cognitive mechanisms rather than only suppressing wakefulness.
Pharmacotherapy may be considered for short-term relief or bridging while CBT-I takes effect. Medication selection depends on patient risk factors, comorbidities, and safety considerations. Agents used in practice may include non-benzodiazepine hypnotics (Z-drugs), benzodiazepine receptor agonists, low-dose doxepin, and melatonin receptor agonists; however, all require careful monitoring for adverse effects such as next-day sedation, falls, cognitive impairment, tolerance, and dependence risk. In older adults, safety concerns are especially important.
Because insomnia can be intertwined with psychological distress, addressing comorbid anxiety, depression, PTSD, or maladaptive coping is clinically essential. Lifestyle measures also support treatment: consistent wake time, controlled light exposure (including morning bright light), limiting evening screen time, reducing caffeine and alcohol, and maintaining regular physical activity. Sleep hygiene alone is not sufficient for chronic insomnia, but it complements CBT-I and improves adherence.
Prognosis varies by phenotype and comorbidity. Many patients improve substantially with CBT-I, and early intervention reduces chronicity. Understanding insomnia as a disorder of arousal and sleep-wake regulation helps shift the framework from “lack of sleep” to a treatable neurobehavioral condition.
Source: @dmanglabjp
Deepak Mangla: Dream is not what you see in sleep; dream is something that does not let you sleep.” Honouring the eternal legacy of Dr. A.P.J. Abdul Kalam on his death anniversary. His vision, humility, and dedication to India will forever remain a source of inspiration.. #breaking
— @dmanglabjp May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
